(0)サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1737450

結核治療薬の世界市場

Tuberculosis Treatment Drugs

出版日
ページ情報
英文 369 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.58円
結核治療薬の世界市場
出版日: 2025年05月30日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 369 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

結核治療薬の世界市場は2030年までに27億米ドルに達する

2024年に22億米ドルと推定される結核治療薬の世界市場は、2024年から2030年にかけてCAGR 3.5％で成長し、2030年には27億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるアクティブ結核治療薬は、CAGR 2.8%を記録し、分析期間終了時には16億米ドルに達すると予測されます。潜在的な結核治療薬セグメントの成長率は、分析期間中CAGR 4.7%と推定されます。

米国市場は5億8,640万米ドルと推定、中国はCAGR6.4％で成長予測

米国の結核治療薬市場は、2024年に5億8,640万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGR6.4%を牽引し、2030年までに5億2,560万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.5%と2.7%と予測されています。欧州では、ドイツがCAGR 2.0%で成長すると予測されています。

世界の結核治療薬市場- 主要動向と促進要因まとめ

結核の治療が依然として世界の公衆衛生の優先課題であるのはなぜか？

結核は、予防も治療も可能であるにもかかわらず、依然として世界の感染症死亡者数の上位を占めています。特に人口が密集し、資源の乏しい地域で結核が蔓延し続けているため、治療薬市場は世界の保健システムにとって極めて重要な要素となっています。イソニアジド、リファンピン、ピラジナミド、エタンブトールの組み合わせからなる標準的な第一選択治療は、薬剤感受性結核に対する有効性が証明されているため、数十年間ほとんど変わっていないです。しかし、治療期間の長さ（通常6ヵ月）、患者のアドヒアランスの悪さ、薬剤耐性結核（DR-TBおよびMDR-TB）の増加率といった課題が、治療成績や公衆衛生管理努力に大きな影響を与えています。これらの要因により、より短期間で安全かつ効果的な薬剤レジメンの開発と普及が急務となっています。このように、世界の結核治療薬市場は、医療上の緊急性と医薬品の技術革新の交差点に位置し、公衆衛生への影響と商業的な可能性の双方に大きな賭けが課せられています。

新薬レジメンと技術革新は治療情勢をどのように変えているのか？

新しい結核治療薬や治療レジメンの導入は、特に薬剤耐性株に対する治療プロトコルを再定義しつつあります。主な画期的治療薬としては、ベダキリン、デラマニド、プレトマニドがあり、これらはWHOが推奨するMDR-TBの治療レジメンに組み込まれ、治療期間を大幅に短縮し、忍容性を向上させています。これらの薬剤を旧来の薬剤と併用することで、痛みを伴う注射の必要性をなくし、重篤な副作用のリスクを軽減する経口レジメンが可能になります。さらに、リファペンチンとモキシフロキサシンを用いた有望な4ヵ月レジメンなど、薬剤感受性の結核に対する治療コースの短縮化に関する調査も進行中です。製薬会社や公衆衛生機関も、宿主指向療法や既存の抗生物質を再利用して免疫反応を高め、治療期間を短縮する方法を模索しています。小児用製剤は、小児の嗜好性と服薬アドヒアランスを改善するために特別に開発されています。さらに、特に識字率が低く、資源に乏しい環境では、投与スケジュールを簡素化し、コンプライアンスを確保するために、合剤が人気を集めています。

政策、アクセス、価格設定の課題は市場をどのように形成しているか？

治療法の進歩にもかかわらず、世界の多くの地域では、有効な結核治療薬へのアクセスが依然として大きな障壁となっています。特に、南アジア、サハラ以南のアフリカ、東欧の一部などの高負担地域では、新薬のコスト、サプライチェーンの複雑さ、脆弱なヘルスケア・インフラが入手を制限しています。知的財産権や特許の制限も、新薬の入手可能性に影響を与えます。こうした課題に対処するため、世界・ドラッグ・ファシリティー（GDF）、ストップ結核パートナーシップ、UNITAIDなどの多国間機関は、価格の引き下げ交渉、ジェネリック医薬品の生産支援、世界の医薬品流通を促進するメカニズムを導入しています。さらに、各国は結核治療を国民皆保険制度に組み入れ、償還政策を強化し、現地での医薬品製造能力を促進しています。規制調和への取り組みにより医薬品の承認が加速化し、臨床試験、データ共有、ファーマコビジランスをめぐる国際的な協力が拡大しています。このような制度的な変化により、市場は徐々に拡大し、世界中の結核患者にとってより公平な治療環境が整いつつあります。

世界の結核治療薬市場拡大の原動力は？

結核治療薬市場の成長は、薬剤耐性結核の罹患率の上昇、医薬品の研究開発に対する公的・民間投資の増加、結核撲滅に焦点を当てた世界ヘルスイニシアチブなど、いくつかの要因によってもたらされています。各国の結核対策プログラムの拡大や、WHOの治療ガイドラインへの新薬の追加は、より広範な採用と市場浸透を促しています。診断ツールの技術的進歩も、より早期かつ正確な発見を可能にし、タイムリーな治療開始を促す役割を果たしています。健康志向の高まりやアドヒアランス支援システムの充実といった消費者行動の動向は、治療の成功率を高め、医薬品需要を促進しています。さらに、小児、HIV感染者、移民といった社会的弱者をターゲットにした医薬品の革新が、対象市場を拡大しています。地域ベースのDOTS（直接観察療法、短期コース）プログラムや遠隔医療支援による結核管理モデルの出現は、医薬品へのアクセスや流通をさらに促進しています。これらすべての要素が、世界の結核治療薬市場の着実かつ長期的な拡大に寄与しています。

セグメント

疾患タイプ（活動性結核、潜在性結核）、治療タイプ（ファーストライン治療、セカンドライン治療）、流通チャネル（病院薬局、ドラッグストア・小売薬局、オンラインプロバイダー）

調査対象企業の例（注目の合計42社）

  • Akorn Operating Company LLC
  • ANI Pharmaceuticals Inc.
  • Cadila Pharmaceuticals Ltd
  • Cipla Limited
  • Endo International plc
  • Fresenius SE & Co. KGaA
  • Hikma Pharmaceuticals PLC
  • Johnson & Johnson
  • LegoChem Biosciences Inc.
  • Lupin Limited
  • Macleods Pharmaceuticals Ltd
  • Merck & Co., Inc.
  • Mylan N.V.（now Viatris Inc.）
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Sanofi
  • Sequella, Inc.
  • STI Pharma LLC
  • Teva Pharmaceutical Industries Ltd.

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP34451

Global Tuberculosis Treatment Drugs Market to Reach US$2.7 Billion by 2030

The global market for Tuberculosis Treatment Drugs estimated at US$2.2 Billion in the year 2024, is expected to reach US$2.7 Billion by 2030, growing at a CAGR of 3.5% over the analysis period 2024-2030. Active Tuberculosis Treatment Drugs, one of the segments analyzed in the report, is expected to record a 2.8% CAGR and reach US$1.6 Billion by the end of the analysis period. Growth in the Latent Tuberculosis Treatment Drugs segment is estimated at 4.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$586.4 Million While China is Forecast to Grow at 6.4% CAGR

The Tuberculosis Treatment Drugs market in the U.S. is estimated at US$586.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$525.6 Million by the year 2030 trailing a CAGR of 6.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.5% and 2.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.0% CAGR.

Global Tuberculosis Treatment Drugs Market - Key Trends & Drivers Summarized

Why Is the Treatment of Tuberculosis Still a Global Public Health Priority?

Tuberculosis (TB) remains one of the top infectious disease killers worldwide, despite being both preventable and treatable. The ongoing prevalence of TB, especially in densely populated and low-resource regions, makes the treatment drugs market a crucial component of global health systems. Standard first-line therapy, consisting of a combination of isoniazid, rifampin, pyrazinamide, and ethambutol, has remained largely unchanged for decades, owing to its proven efficacy in drug-susceptible TB. However, challenges such as long treatment durations (typically six months), poor patient adherence, and rising rates of drug-resistant TB (DR-TB and MDR-TB) have significantly impacted treatment outcomes and public health control efforts. These factors have spurred urgent calls for the development and dissemination of shorter, safer, and more effective drug regimens. The global TB drugs market thus sits at the intersection of medical urgency and pharmaceutical innovation, with high stakes for both public health impact and commercial potential.

How Are New Drug Regimens and Innovations Transforming the Treatment Landscape?

The introduction of novel TB treatment drugs and regimens is redefining therapeutic protocols, especially for drug-resistant strains. Key breakthroughs include bedaquiline, delamanid, and pretomanid, which have been incorporated into WHO-recommended regimens for MDR-TB, significantly reducing treatment duration and improving tolerability. These drugs, when used in combination with older agents, are enabling all-oral regimens that eliminate the need for painful injections and mitigate the risk of serious side effects. Additionally, research is ongoing into shorter treatment courses for drug-sensitive TB, including the promising 4-month regimen using rifapentine and moxifloxacin. Pharmaceutical companies and public health organizations are also exploring host-directed therapies and repurposing existing antibiotics to boost immune responses and shorten therapy durations. Pediatric formulations are being specially developed to improve palatability and adherence in children. Moreover, fixed-dose combination pills are gaining popularity for simplifying dosing schedules and ensuring compliance, especially in low-literacy and resource-limited settings.

How Are Policy, Access, and Pricing Challenges Shaping the Market?

Despite advancements in treatment, access to effective TB drugs remains a significant barrier in many parts of the world. The cost of new drugs, supply chain complexities, and weak healthcare infrastructure limit availability, particularly in high-burden regions such as South Asia, Sub-Saharan Africa, and parts of Eastern Europe. Intellectual property rights and patent restrictions also affect the affordability of newer medications. To address these challenges, multilateral agencies such as the Global Drug Facility (GDF), the Stop TB Partnership, and UNITAID have implemented mechanisms to negotiate lower prices, support generic production, and facilitate global drug distribution. Furthermore, countries are incorporating TB treatment into universal health coverage schemes, enhancing reimbursement policies, and promoting local drug manufacturing capabilities. Regulatory harmonization efforts are accelerating drug approvals, and international collaboration is growing around clinical trials, data sharing, and pharmacovigilance. These systemic changes are gradually increasing market reach and building a more equitable treatment landscape for TB patients worldwide.

What Is Fueling Market Expansion for TB Treatment Drugs Globally?

The growth in the tuberculosis treatment drugs market is driven by several factors, including the rising incidence of drug-resistant TB, increasing public and private investment in pharmaceutical R&D, and global health initiatives focused on TB eradication. The expansion of national TB control programs and the inclusion of new drugs in WHO treatment guidelines are encouraging wider adoption and market uptake. Technological advancements in diagnostic tools are also playing a role by enabling earlier and more accurate detection, thus driving timely initiation of therapy. Consumer behavior trends, including higher health-seeking behavior and better adherence support systems, are increasing treatment success rates and fueling drug demand. Moreover, pharmaceutical innovation targeting vulnerable populations - such as children, people living with HIV, and migrants - is expanding the target market. The emergence of community-based DOTS (Directly Observed Therapy, Short-Course) programs and telehealth-supported TB management models are further pushing the accessibility and distribution of medications. All these elements are contributing to a steady, long-term expansion of the global TB treatment drugs market.

SCOPE OF STUDY:

The report analyzes the Tuberculosis Treatment Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Disease Type (Active Tuberculosis, Latent Tuberculosis); Therapy Type (First Line Therapy, Second Line Therapy); Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, Online Providers)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • Akorn Operating Company LLC
  • ANI Pharmaceuticals Inc.
  • Cadila Pharmaceuticals Ltd
  • Cipla Limited
  • Endo International plc
  • Fresenius SE & Co. KGaA
  • Hikma Pharmaceuticals PLC
  • Johnson & Johnson
  • LegoChem Biosciences Inc.
  • Lupin Limited
  • Macleods Pharmaceuticals Ltd
  • Merck & Co., Inc.
  • Mylan N.V. (now Viatris Inc.)
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Sanofi
  • Sequella, Inc.
  • STI Pharma LLC
  • Teva Pharmaceutical Industries Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Tuberculosis Treatment Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increase in Multidrug-Resistant TB Cases Drives Demand for Novel Antimicrobials
    • Shorter-Duration Drug Regimens Spur Patient Adherence and Expand Market Reach
    • Regulatory Approvals of All-Oral Regimens Strengthen Business Case for Next-Gen TB Therapies
    • Inclusion of TB Treatment in National Reimbursement Lists Drives Access in Low-Income Regions
    • Public-Private R&D Partnerships Accelerate Innovation in TB Drug Development
    • Increasing Global Advocacy and Awareness Campaigns Generate Treatment Uptake
    • Development of Pediatric-Specific Formulations Expands Addressable Patient Base
    • Expansion of Community-Based DOTS Programs Spurs Demand for Fixed-Dose Combinations
    • High Failure Rates of Legacy Treatments Propel Investment in Bedaquiline-Based Therapies
    • Rise of Decentralized Treatment Models Enhances Distribution of Essential TB Medications
    • Growth of Local Generic Drug Manufacturing Strengthens Drug Accessibility in Emerging Markets
    • Demand for Heat-Stable and Shelf-Stable Drug Forms Fuels Innovation in Formulation Technology
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Tuberculosis Treatment Drugs Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Tuberculosis Treatment Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Tuberculosis Treatment Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Active Tuberculosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Active Tuberculosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Active Tuberculosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Latent Tuberculosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Latent Tuberculosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Latent Tuberculosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for First Line Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for First Line Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for First Line Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Second Line Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Second Line Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Second Line Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Drug Stores & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Drug Stores & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Drug Stores & Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Online Providers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Online Providers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Online Providers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Tuberculosis Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Disease Type - Active Tuberculosis and Latent Tuberculosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Tuberculosis Treatment Drugs by Disease Type - Active Tuberculosis and Latent Tuberculosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for Tuberculosis Treatment Drugs by Disease Type - Percentage Breakdown of Value Sales for Active Tuberculosis and Latent Tuberculosis for the Years 2015, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Therapy Type - First Line Therapy and Second Line Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Tuberculosis Treatment Drugs by Therapy Type - First Line Therapy and Second Line Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Tuberculosis Treatment Drugs by Therapy Type - Percentage Breakdown of Value Sales for First Line Therapy and Second Line Therapy for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Tuberculosis Treatment Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Tuberculosis Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Disease Type - Active Tuberculosis and Latent Tuberculosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Tuberculosis Treatment Drugs by Disease Type - Active Tuberculosis and Latent Tuberculosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Tuberculosis Treatment Drugs by Disease Type - Percentage Breakdown of Value Sales for Active Tuberculosis and Latent Tuberculosis for the Years 2015, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Therapy Type - First Line Therapy and Second Line Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Tuberculosis Treatment Drugs by Therapy Type - First Line Therapy and Second Line Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Tuberculosis Treatment Drugs by Therapy Type - Percentage Breakdown of Value Sales for First Line Therapy and Second Line Therapy for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Tuberculosis Treatment Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Tuberculosis Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • JAPAN
    • Tuberculosis Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Disease Type - Active Tuberculosis and Latent Tuberculosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Tuberculosis Treatment Drugs by Disease Type - Active Tuberculosis and Latent Tuberculosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Tuberculosis Treatment Drugs by Disease Type - Percentage Breakdown of Value Sales for Active Tuberculosis and Latent Tuberculosis for the Years 2015, 2025 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Therapy Type - First Line Therapy and Second Line Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Tuberculosis Treatment Drugs by Therapy Type - First Line Therapy and Second Line Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Tuberculosis Treatment Drugs by Therapy Type - Percentage Breakdown of Value Sales for First Line Therapy and Second Line Therapy for the Years 2015, 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Tuberculosis Treatment Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Tuberculosis Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • CHINA
    • Tuberculosis Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 53: China Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Disease Type - Active Tuberculosis and Latent Tuberculosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Tuberculosis Treatment Drugs by Disease Type - Active Tuberculosis and Latent Tuberculosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: China 15-Year Perspective for Tuberculosis Treatment Drugs by Disease Type - Percentage Breakdown of Value Sales for Active Tuberculosis and Latent Tuberculosis for the Years 2015, 2025 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Therapy Type - First Line Therapy and Second Line Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Tuberculosis Treatment Drugs by Therapy Type - First Line Therapy and Second Line Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: China 15-Year Perspective for Tuberculosis Treatment Drugs by Therapy Type - Percentage Breakdown of Value Sales for First Line Therapy and Second Line Therapy for the Years 2015, 2025 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Tuberculosis Treatment Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Tuberculosis Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • EUROPE
    • Tuberculosis Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Tuberculosis Treatment Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Europe 15-Year Perspective for Tuberculosis Treatment Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Disease Type - Active Tuberculosis and Latent Tuberculosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Tuberculosis Treatment Drugs by Disease Type - Active Tuberculosis and Latent Tuberculosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Europe 15-Year Perspective for Tuberculosis Treatment Drugs by Disease Type - Percentage Breakdown of Value Sales for Active Tuberculosis and Latent Tuberculosis for the Years 2015, 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Therapy Type - First Line Therapy and Second Line Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Tuberculosis Treatment Drugs by Therapy Type - First Line Therapy and Second Line Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Tuberculosis Treatment Drugs by Therapy Type - Percentage Breakdown of Value Sales for First Line Therapy and Second Line Therapy for the Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Tuberculosis Treatment Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Tuberculosis Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • FRANCE
    • Tuberculosis Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 74: France Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Disease Type - Active Tuberculosis and Latent Tuberculosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: France Historic Review for Tuberculosis Treatment Drugs by Disease Type - Active Tuberculosis and Latent Tuberculosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: France 15-Year Perspective for Tuberculosis Treatment Drugs by Disease Type - Percentage Breakdown of Value Sales for Active Tuberculosis and Latent Tuberculosis for the Years 2015, 2025 & 2030
    • TABLE 77: France Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Therapy Type - First Line Therapy and Second Line Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Tuberculosis Treatment Drugs by Therapy Type - First Line Therapy and Second Line Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: France 15-Year Perspective for Tuberculosis Treatment Drugs by Therapy Type - Percentage Breakdown of Value Sales for First Line Therapy and Second Line Therapy for the Years 2015, 2025 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Tuberculosis Treatment Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for Tuberculosis Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • GERMANY
    • Tuberculosis Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 83: Germany Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Disease Type - Active Tuberculosis and Latent Tuberculosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Germany Historic Review for Tuberculosis Treatment Drugs by Disease Type - Active Tuberculosis and Latent Tuberculosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Germany 15-Year Perspective for Tuberculosis Treatment Drugs by Disease Type - Percentage Breakdown of Value Sales for Active Tuberculosis and Latent Tuberculosis for the Years 2015, 2025 & 2030
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Therapy Type - First Line Therapy and Second Line Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Germany Historic Review for Tuberculosis Treatment Drugs by Therapy Type - First Line Therapy and Second Line Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Germany 15-Year Perspective for Tuberculosis Treatment Drugs by Therapy Type - Percentage Breakdown of Value Sales for First Line Therapy and Second Line Therapy for the Years 2015, 2025 & 2030
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Tuberculosis Treatment Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for Tuberculosis Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 92: Italy Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Disease Type - Active Tuberculosis and Latent Tuberculosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Italy Historic Review for Tuberculosis Treatment Drugs by Disease Type - Active Tuberculosis and Latent Tuberculosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Italy 15-Year Perspective for Tuberculosis Treatment Drugs by Disease Type - Percentage Breakdown of Value Sales for Active Tuberculosis and Latent Tuberculosis for the Years 2015, 2025 & 2030
    • TABLE 95: Italy Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Therapy Type - First Line Therapy and Second Line Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Italy Historic Review for Tuberculosis Treatment Drugs by Therapy Type - First Line Therapy and Second Line Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Italy 15-Year Perspective for Tuberculosis Treatment Drugs by Therapy Type - Percentage Breakdown of Value Sales for First Line Therapy and Second Line Therapy for the Years 2015, 2025 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Tuberculosis Treatment Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for Tuberculosis Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Tuberculosis Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 101: UK Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Disease Type - Active Tuberculosis and Latent Tuberculosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: UK Historic Review for Tuberculosis Treatment Drugs by Disease Type - Active Tuberculosis and Latent Tuberculosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: UK 15-Year Perspective for Tuberculosis Treatment Drugs by Disease Type - Percentage Breakdown of Value Sales for Active Tuberculosis and Latent Tuberculosis for the Years 2015, 2025 & 2030
    • TABLE 104: UK Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Therapy Type - First Line Therapy and Second Line Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK Historic Review for Tuberculosis Treatment Drugs by Therapy Type - First Line Therapy and Second Line Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: UK 15-Year Perspective for Tuberculosis Treatment Drugs by Therapy Type - Percentage Breakdown of Value Sales for First Line Therapy and Second Line Therapy for the Years 2015, 2025 & 2030
    • TABLE 107: UK Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Tuberculosis Treatment Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for Tuberculosis Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 110: Spain Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Disease Type - Active Tuberculosis and Latent Tuberculosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Spain Historic Review for Tuberculosis Treatment Drugs by Disease Type - Active Tuberculosis and Latent Tuberculosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Spain 15-Year Perspective for Tuberculosis Treatment Drugs by Disease Type - Percentage Breakdown of Value Sales for Active Tuberculosis and Latent Tuberculosis for the Years 2015, 2025 & 2030
    • TABLE 113: Spain Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Therapy Type - First Line Therapy and Second Line Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Spain Historic Review for Tuberculosis Treatment Drugs by Therapy Type - First Line Therapy and Second Line Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Spain 15-Year Perspective for Tuberculosis Treatment Drugs by Therapy Type - Percentage Breakdown of Value Sales for First Line Therapy and Second Line Therapy for the Years 2015, 2025 & 2030
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Tuberculosis Treatment Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Spain 15-Year Perspective for Tuberculosis Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 119: Russia Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Disease Type - Active Tuberculosis and Latent Tuberculosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Russia Historic Review for Tuberculosis Treatment Drugs by Disease Type - Active Tuberculosis and Latent Tuberculosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Russia 15-Year Perspective for Tuberculosis Treatment Drugs by Disease Type - Percentage Breakdown of Value Sales for Active Tuberculosis and Latent Tuberculosis for the Years 2015, 2025 & 2030
    • TABLE 122: Russia Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Therapy Type - First Line Therapy and Second Line Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Russia Historic Review for Tuberculosis Treatment Drugs by Therapy Type - First Line Therapy and Second Line Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Russia 15-Year Perspective for Tuberculosis Treatment Drugs by Therapy Type - Percentage Breakdown of Value Sales for First Line Therapy and Second Line Therapy for the Years 2015, 2025 & 2030
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Tuberculosis Treatment Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Russia 15-Year Perspective for Tuberculosis Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 128: Rest of Europe Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Disease Type - Active Tuberculosis and Latent Tuberculosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Europe Historic Review for Tuberculosis Treatment Drugs by Disease Type - Active Tuberculosis and Latent Tuberculosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of Europe 15-Year Perspective for Tuberculosis Treatment Drugs by Disease Type - Percentage Breakdown of Value Sales for Active Tuberculosis and Latent Tuberculosis for the Years 2015, 2025 & 2030
    • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Therapy Type - First Line Therapy and Second Line Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Europe Historic Review for Tuberculosis Treatment Drugs by Therapy Type - First Line Therapy and Second Line Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Europe 15-Year Perspective for Tuberculosis Treatment Drugs by Therapy Type - Percentage Breakdown of Value Sales for First Line Therapy and Second Line Therapy for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Tuberculosis Treatment Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 15-Year Perspective for Tuberculosis Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Tuberculosis Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 137: Asia-Pacific Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 138: Asia-Pacific Historic Review for Tuberculosis Treatment Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Asia-Pacific 15-Year Perspective for Tuberculosis Treatment Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Disease Type - Active Tuberculosis and Latent Tuberculosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Asia-Pacific Historic Review for Tuberculosis Treatment Drugs by Disease Type - Active Tuberculosis and Latent Tuberculosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Asia-Pacific 15-Year Perspective for Tuberculosis Treatment Drugs by Disease Type - Percentage Breakdown of Value Sales for Active Tuberculosis and Latent Tuberculosis for the Years 2015, 2025 & 2030
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Therapy Type - First Line Therapy and Second Line Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Tuberculosis Treatment Drugs by Therapy Type - First Line Therapy and Second Line Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 15-Year Perspective for Tuberculosis Treatment Drugs by Therapy Type - Percentage Breakdown of Value Sales for First Line Therapy and Second Line Therapy for the Years 2015, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Tuberculosis Treatment Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for Tuberculosis Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Tuberculosis Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 149: Australia Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Disease Type - Active Tuberculosis and Latent Tuberculosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Australia Historic Review for Tuberculosis Treatment Drugs by Disease Type - Active Tuberculosis and Latent Tuberculosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Australia 15-Year Perspective for Tuberculosis Treatment Drugs by Disease Type - Percentage Breakdown of Value Sales for Active Tuberculosis and Latent Tuberculosis for the Years 2015, 2025 & 2030
    • TABLE 152: Australia Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Therapy Type - First Line Therapy and Second Line Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Australia Historic Review for Tuberculosis Treatment Drugs by Therapy Type - First Line Therapy and Second Line Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Australia 15-Year Perspective for Tuberculosis Treatment Drugs by Therapy Type - Percentage Breakdown of Value Sales for First Line Therapy and Second Line Therapy for the Years 2015, 2025 & 2030
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Tuberculosis Treatment Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Australia 15-Year Perspective for Tuberculosis Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • INDIA
    • Tuberculosis Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 158: India Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Disease Type - Active Tuberculosis and Latent Tuberculosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: India Historic Review for Tuberculosis Treatment Drugs by Disease Type - Active Tuberculosis and Latent Tuberculosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: India 15-Year Perspective for Tuberculosis Treatment Drugs by Disease Type - Percentage Breakdown of Value Sales for Active Tuberculosis and Latent Tuberculosis for the Years 2015, 2025 & 2030
    • TABLE 161: India Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Therapy Type - First Line Therapy and Second Line Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: India Historic Review for Tuberculosis Treatment Drugs by Therapy Type - First Line Therapy and Second Line Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: India 15-Year Perspective for Tuberculosis Treatment Drugs by Therapy Type - Percentage Breakdown of Value Sales for First Line Therapy and Second Line Therapy for the Years 2015, 2025 & 2030
    • TABLE 164: India Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Tuberculosis Treatment Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: India 15-Year Perspective for Tuberculosis Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 167: South Korea Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Disease Type - Active Tuberculosis and Latent Tuberculosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: South Korea Historic Review for Tuberculosis Treatment Drugs by Disease Type - Active Tuberculosis and Latent Tuberculosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: South Korea 15-Year Perspective for Tuberculosis Treatment Drugs by Disease Type - Percentage Breakdown of Value Sales for Active Tuberculosis and Latent Tuberculosis for the Years 2015, 2025 & 2030
    • TABLE 170: South Korea Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Therapy Type - First Line Therapy and Second Line Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: South Korea Historic Review for Tuberculosis Treatment Drugs by Therapy Type - First Line Therapy and Second Line Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: South Korea 15-Year Perspective for Tuberculosis Treatment Drugs by Therapy Type - Percentage Breakdown of Value Sales for First Line Therapy and Second Line Therapy for the Years 2015, 2025 & 2030
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Tuberculosis Treatment Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: South Korea 15-Year Perspective for Tuberculosis Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 176: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Disease Type - Active Tuberculosis and Latent Tuberculosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Rest of Asia-Pacific Historic Review for Tuberculosis Treatment Drugs by Disease Type - Active Tuberculosis and Latent Tuberculosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Rest of Asia-Pacific 15-Year Perspective for Tuberculosis Treatment Drugs by Disease Type - Percentage Breakdown of Value Sales for Active Tuberculosis and Latent Tuberculosis for the Years 2015, 2025 & 2030
    • TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Therapy Type - First Line Therapy and Second Line Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Rest of Asia-Pacific Historic Review for Tuberculosis Treatment Drugs by Therapy Type - First Line Therapy and Second Line Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Rest of Asia-Pacific 15-Year Perspective for Tuberculosis Treatment Drugs by Therapy Type - Percentage Breakdown of Value Sales for First Line Therapy and Second Line Therapy for the Years 2015, 2025 & 2030
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Tuberculosis Treatment Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Tuberculosis Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Tuberculosis Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 185: Latin America Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 186: Latin America Historic Review for Tuberculosis Treatment Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Latin America 15-Year Perspective for Tuberculosis Treatment Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 188: Latin America Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Disease Type - Active Tuberculosis and Latent Tuberculosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Latin America Historic Review for Tuberculosis Treatment Drugs by Disease Type - Active Tuberculosis and Latent Tuberculosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Latin America 15-Year Perspective for Tuberculosis Treatment Drugs by Disease Type - Percentage Breakdown of Value Sales for Active Tuberculosis and Latent Tuberculosis for the Years 2015, 2025 & 2030
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Therapy Type - First Line Therapy and Second Line Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Tuberculosis Treatment Drugs by Therapy Type - First Line Therapy and Second Line Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Latin America 15-Year Perspective for Tuberculosis Treatment Drugs by Therapy Type - Percentage Breakdown of Value Sales for First Line Therapy and Second Line Therapy for the Years 2015, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Tuberculosis Treatment Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Latin America 15-Year Perspective for Tuberculosis Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 197: Argentina Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Disease Type - Active Tuberculosis and Latent Tuberculosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Argentina Historic Review for Tuberculosis Treatment Drugs by Disease Type - Active Tuberculosis and Latent Tuberculosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Argentina 15-Year Perspective for Tuberculosis Treatment Drugs by Disease Type - Percentage Breakdown of Value Sales for Active Tuberculosis and Latent Tuberculosis for the Years 2015, 2025 & 2030
    • TABLE 200: Argentina Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Therapy Type - First Line Therapy and Second Line Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Argentina Historic Review for Tuberculosis Treatment Drugs by Therapy Type - First Line Therapy and Second Line Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Argentina 15-Year Perspective for Tuberculosis Treatment Drugs by Therapy Type - Percentage Breakdown of Value Sales for First Line Therapy and Second Line Therapy for the Years 2015, 2025 & 2030
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Tuberculosis Treatment Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Argentina 15-Year Perspective for Tuberculosis Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 206: Brazil Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Disease Type - Active Tuberculosis and Latent Tuberculosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Brazil Historic Review for Tuberculosis Treatment Drugs by Disease Type - Active Tuberculosis and Latent Tuberculosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Brazil 15-Year Perspective for Tuberculosis Treatment Drugs by Disease Type - Percentage Breakdown of Value Sales for Active Tuberculosis and Latent Tuberculosis for the Years 2015, 2025 & 2030
    • TABLE 209: Brazil Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Therapy Type - First Line Therapy and Second Line Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Brazil Historic Review for Tuberculosis Treatment Drugs by Therapy Type - First Line Therapy and Second Line Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Brazil 15-Year Perspective for Tuberculosis Treatment Drugs by Therapy Type - Percentage Breakdown of Value Sales for First Line Therapy and Second Line Therapy for the Years 2015, 2025 & 2030
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Tuberculosis Treatment Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Brazil 15-Year Perspective for Tuberculosis Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 215: Mexico Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Disease Type - Active Tuberculosis and Latent Tuberculosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Mexico Historic Review for Tuberculosis Treatment Drugs by Disease Type - Active Tuberculosis and Latent Tuberculosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Mexico 15-Year Perspective for Tuberculosis Treatment Drugs by Disease Type - Percentage Breakdown of Value Sales for Active Tuberculosis and Latent Tuberculosis for the Years 2015, 2025 & 2030
    • TABLE 218: Mexico Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Therapy Type - First Line Therapy and Second Line Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Mexico Historic Review for Tuberculosis Treatment Drugs by Therapy Type - First Line Therapy and Second Line Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Mexico 15-Year Perspective for Tuberculosis Treatment Drugs by Therapy Type - Percentage Breakdown of Value Sales for First Line Therapy and Second Line Therapy for the Years 2015, 2025 & 2030
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Tuberculosis Treatment Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Mexico 15-Year Perspective for Tuberculosis Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 224: Rest of Latin America Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Disease Type - Active Tuberculosis and Latent Tuberculosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Rest of Latin America Historic Review for Tuberculosis Treatment Drugs by Disease Type - Active Tuberculosis and Latent Tuberculosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Rest of Latin America 15-Year Perspective for Tuberculosis Treatment Drugs by Disease Type - Percentage Breakdown of Value Sales for Active Tuberculosis and Latent Tuberculosis for the Years 2015, 2025 & 2030
    • TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Therapy Type - First Line Therapy and Second Line Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Rest of Latin America Historic Review for Tuberculosis Treatment Drugs by Therapy Type - First Line Therapy and Second Line Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Rest of Latin America 15-Year Perspective for Tuberculosis Treatment Drugs by Therapy Type - Percentage Breakdown of Value Sales for First Line Therapy and Second Line Therapy for the Years 2015, 2025 & 2030
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Tuberculosis Treatment Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 15-Year Perspective for Tuberculosis Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Tuberculosis Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 233: Middle East Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 234: Middle East Historic Review for Tuberculosis Treatment Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Middle East 15-Year Perspective for Tuberculosis Treatment Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 236: Middle East Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Disease Type - Active Tuberculosis and Latent Tuberculosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Middle East Historic Review for Tuberculosis Treatment Drugs by Disease Type - Active Tuberculosis and Latent Tuberculosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Middle East 15-Year Perspective for Tuberculosis Treatment Drugs by Disease Type - Percentage Breakdown of Value Sales for Active Tuberculosis and Latent Tuberculosis for the Years 2015, 2025 & 2030
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Therapy Type - First Line Therapy and Second Line Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Tuberculosis Treatment Drugs by Therapy Type - First Line Therapy and Second Line Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Middle East 15-Year Perspective for Tuberculosis Treatment Drugs by Therapy Type - Percentage Breakdown of Value Sales for First Line Therapy and Second Line Therapy for the Years 2015, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Tuberculosis Treatment Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Middle East 15-Year Perspective for Tuberculosis Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 245: Iran Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Disease Type - Active Tuberculosis and Latent Tuberculosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Iran Historic Review for Tuberculosis Treatment Drugs by Disease Type - Active Tuberculosis and Latent Tuberculosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Iran 15-Year Perspective for Tuberculosis Treatment Drugs by Disease Type - Percentage Breakdown of Value Sales for Active Tuberculosis and Latent Tuberculosis for the Years 2015, 2025 & 2030
    • TABLE 248: Iran Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Therapy Type - First Line Therapy and Second Line Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Iran Historic Review for Tuberculosis Treatment Drugs by Therapy Type - First Line Therapy and Second Line Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Iran 15-Year Perspective for Tuberculosis Treatment Drugs by Therapy Type - Percentage Breakdown of Value Sales for First Line Therapy and Second Line Therapy for the Years 2015, 2025 & 2030
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Tuberculosis Treatment Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Iran 15-Year Perspective for Tuberculosis Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 254: Israel Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Disease Type - Active Tuberculosis and Latent Tuberculosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Israel Historic Review for Tuberculosis Treatment Drugs by Disease Type - Active Tuberculosis and Latent Tuberculosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Israel 15-Year Perspective for Tuberculosis Treatment Drugs by Disease Type - Percentage Breakdown of Value Sales for Active Tuberculosis and Latent Tuberculosis for the Years 2015, 2025 & 2030
    • TABLE 257: Israel Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Therapy Type - First Line Therapy and Second Line Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Israel Historic Review for Tuberculosis Treatment Drugs by Therapy Type - First Line Therapy and Second Line Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Israel 15-Year Perspective for Tuberculosis Treatment Drugs by Therapy Type - Percentage Breakdown of Value Sales for First Line Therapy and Second Line Therapy for the Years 2015, 2025 & 2030
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Tuberculosis Treatment Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Israel 15-Year Perspective for Tuberculosis Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 263: Saudi Arabia Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Disease Type - Active Tuberculosis and Latent Tuberculosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Saudi Arabia Historic Review for Tuberculosis Treatment Drugs by Disease Type - Active Tuberculosis and Latent Tuberculosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Saudi Arabia 15-Year Perspective for Tuberculosis Treatment Drugs by Disease Type - Percentage Breakdown of Value Sales for Active Tuberculosis and Latent Tuberculosis for the Years 2015, 2025 & 2030
    • TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Therapy Type - First Line Therapy and Second Line Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Saudi Arabia Historic Review for Tuberculosis Treatment Drugs by Therapy Type - First Line Therapy and Second Line Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Saudi Arabia 15-Year Perspective for Tuberculosis Treatment Drugs by Therapy Type - Percentage Breakdown of Value Sales for First Line Therapy and Second Line Therapy for the Years 2015, 2025 & 2030
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Tuberculosis Treatment Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 15-Year Perspective for Tuberculosis Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 272: UAE Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Disease Type - Active Tuberculosis and Latent Tuberculosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: UAE Historic Review for Tuberculosis Treatment Drugs by Disease Type - Active Tuberculosis and Latent Tuberculosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: UAE 15-Year Perspective for Tuberculosis Treatment Drugs by Disease Type - Percentage Breakdown of Value Sales for Active Tuberculosis and Latent Tuberculosis for the Years 2015, 2025 & 2030
    • TABLE 275: UAE Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Therapy Type - First Line Therapy and Second Line Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: UAE Historic Review for Tuberculosis Treatment Drugs by Therapy Type - First Line Therapy and Second Line Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: UAE 15-Year Perspective for Tuberculosis Treatment Drugs by Therapy Type - Percentage Breakdown of Value Sales for First Line Therapy and Second Line Therapy for the Years 2015, 2025 & 2030
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Tuberculosis Treatment Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: UAE 15-Year Perspective for Tuberculosis Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 281: Rest of Middle East Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Disease Type - Active Tuberculosis and Latent Tuberculosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Rest of Middle East Historic Review for Tuberculosis Treatment Drugs by Disease Type - Active Tuberculosis and Latent Tuberculosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: Rest of Middle East 15-Year Perspective for Tuberculosis Treatment Drugs by Disease Type - Percentage Breakdown of Value Sales for Active Tuberculosis and Latent Tuberculosis for the Years 2015, 2025 & 2030
    • TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Therapy Type - First Line Therapy and Second Line Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Rest of Middle East Historic Review for Tuberculosis Treatment Drugs by Therapy Type - First Line Therapy and Second Line Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: Rest of Middle East 15-Year Perspective for Tuberculosis Treatment Drugs by Therapy Type - Percentage Breakdown of Value Sales for First Line Therapy and Second Line Therapy for the Years 2015, 2025 & 2030
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Tuberculosis Treatment Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 15-Year Perspective for Tuberculosis Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • AFRICA
    • Tuberculosis Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 290: Africa Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Disease Type - Active Tuberculosis and Latent Tuberculosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Africa Historic Review for Tuberculosis Treatment Drugs by Disease Type - Active Tuberculosis and Latent Tuberculosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Africa 15-Year Perspective for Tuberculosis Treatment Drugs by Disease Type - Percentage Breakdown of Value Sales for Active Tuberculosis and Latent Tuberculosis for the Years 2015, 2025 & 2030
    • TABLE 293: Africa Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Therapy Type - First Line Therapy and Second Line Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Africa Historic Review for Tuberculosis Treatment Drugs by Therapy Type - First Line Therapy and Second Line Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Africa 15-Year Perspective for Tuberculosis Treatment Drugs by Therapy Type - Percentage Breakdown of Value Sales for First Line Therapy and Second Line Therapy for the Years 2015, 2025 & 2030
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Tuberculosis Treatment Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Tuberculosis Treatment Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Africa 15-Year Perspective for Tuberculosis Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030

IV. COMPETITION